| 6 | Diarrhoea in a patient with metastatic melanoma:Ipilimumab ileocolitis treated with infliximab显示文摘Administration of ipilimumab,a cytotoxic T-lymphocyte associated antigen-4-blocking monoclonal antibody,leads to enhancement of the anti-tumor T-cell respons and as a result shows a significant survival benefit in metastatic melanoma patients.Therefore patients are currently receiving this promising therapy as a secondline strategy.Unfortunately,by activation of the T-cell immune reponse,ipilimumab therapy may lead to an unwanted induction of different autoimmune phenomena.Diarrhoea and colitis occur in up to one third of patients.Here we present a case of ipilimumab induced ileocolitis which was successfully treated with infliximab,an anti-tumor necrosis factor monoclonal antibody,after corticosteroid therapy failure.Although formal trials are lacking,recently publicated series suggest that infusional therapy of infliximab is effective in ipilimumab induced ileocolitis. | Rob ME Slangen Alfonsus JM van den Eertwegh Adriaan A van Bodegraven Nanne KH de Boer | 2013 | World Journal of Gastrointestinal Pharmacology and Therapeutics2013，4，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员